<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467478</url>
  </required_header>
  <id_info>
    <org_study_id>121439</org_study_id>
    <nct_id>NCT02467478</nct_id>
  </id_info>
  <brief_title>Linagliptin's Effect on CD34+ Stem Cells</brief_title>
  <official_title>Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels
      which may contribute to heart disease. Endothelial Progenitor Cells (EPCs) are found in the
      blood. Research has shown that improving the survival of these special blood cells may
      decrease the harmful effects of diabetes on blood vessels and reduce or reverse heart
      disease. Linagliptin is an Food and Drug Administration (FDA) approved prescription medicine
      used along with insulin or with oral medications to lower blood sugar in people with Type 2
      diabetes. It is in a class of diabetes medication called Dipeptidyl peptidase-4 (DPP-4)
      inhibitors. DPP-4 inhibitors have been shown to increase EPCs in patients with Type 2
      diabetes.

      Hypothesis: Both type 2 diabetes and Chronic Kidney Disease (CKD) are associated with poor
      stem cell number and function. Poor viability and function of EPCs in CKD and diabetes The
      investigators hypothesize that use of Linagliptin (along with Insulin) may help reduce
      cardiovascular risk by improving EPC survival and function above and beyond adequate glucose
      metabolism control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a national epidemic with significant macro and microvascular
      complications. Insulin resistance in pre-diabetes and overt diabetes are associated with
      endothelial dysfunction.

      A few studies indicate that stem cells particularly EPCs can act as a suitable bio-marker for
      monitoring cardiovascular morbidity. In this proposal the investigators suggest that EPCs or
      CD34 positive cells (defined as CD34/vascular endothelial growth factor receptor 2 (VEGFR2+)
      cells) can act as a suitable cellular biomarker for estimating and following endothelial
      dysfunction in early type 2 diabetes patients with CKD. EPCs have been shown to be
      dysfunctional in both CKD patients and type 2 Diabetes Mellitus (DM) patients.

      Linagliptin (TRADJENTA) tablets are indicated as an adjunct to diet and exercise to improve
      glycemic control in adults with type 2 diabetes mellitus. No dose adjustment is recommended
      for patients with renal impairment.

      EPCs have been used as a regenerative tool in ischemic myocardium and diabetic wound healing.
      Endothelial dysfunction with associated inflammation may be a consequence of excess
      intra-cellular super-oxide presence in a setting of diabetes which is a pro-oxidative stress
      condition ultimately leading to poor EPC function and senescence.

      Though lifestyle modification has been proposed as a main stay for prevention and treatment
      of early type 2 diabetes, several new therapies for diabetes have been developed in recent
      years. Incretins and incretin mimetics appear to hold promise. Mechanism of positive effect
      of exercise and oral hypoglycemic agents can be very different.

      DPP-4 inhibitors have been shown to increase EPCs in patients with type 2 diabetes reportedly
      via stromal cell-derived factor 1 (SDF-1) alpha up-regulation. Interestingly, up-regulation
      of SDF-1 alpha and vascular endothelial growth factor (VEGF), both chemotactic factors
      increase mobilization and recruitment of EPCs in the face of acute ischemic injury for repair
      and regeneration.

      Several studies have shown positive effect of incretins (Glucagon like peptide, GLP-1) and
      incretin receptor agonists (GLP-1 receptor agonists) on cardiovascular risk factors in type 2
      diabetes patients and even in patients with chronic heart failure and left ventricular
      dysfunction who do not have diabetes.

      DPP-4 Inhibitors may have cardio-protective effects of their own, as they increase
      bio-availability of endogenous GLP-1. They improve blood flow and nitric oxide production in
      endothelium. These are unique properties not demonstrated by other oral diabetes medications.
      The mechanism underlying these effects may be mediated by increased nitric oxide
      bioavailability but is not completely known. However these beneficial effects appear to be
      independent of glycemia reduction.

      It is however unknown whether Linagliptin will have any positive effect on human EPC function
      where two prominent cardiovascular risk factors co-exist such as CKD and type 2 diabetes.

      Therefore the investigators plan to investigate if Linagliptin can alter function and gene
      expression of CD34+ cells in a setting of CKD and type 2 diabetes. The investigators choose
      to look at non geriatric adult population with early type 2 diabetes (less than 10 years of
      duration) at an early phase of renal impairment (stages 1-3).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular Markers</measure>
    <time_frame>Up to 12 weeks post Linagliptin</time_frame>
    <description>The investigators will use participants' peripheral blood derived CD34+ cells looking at number, function, and gene expression. This will be correlated to improvement in 24hr urinary protein estimation and creatinine clearance. Post Linagliptin will be compared to pre Linagliptin measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Function Marker in CKD</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>We measure using microalbumin/creatinine ratio provided from a random spot urine sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Endothelial Inflammatory Markers</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>Serum endothelial inflammatory markers will include: high sensitivity C-reactive protein (hs-CRP), IL-6, and TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid profile</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>Measured through serum biochemistry Lipid Panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>Glycemic control is evaluated by measuring fasting blood glucose, insulin, and HbA1c levels and assessing insulin resistance using homeostatic model assessment insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiposity</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>Measured using the Tanita Body Composition Analyzer scale, measured as percentage body fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Creatinine clearance</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>Measured via blood biochemistry eGFR, and spot urine urine microalbumin/creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel Health</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>Vessel health is assessed by looking at systolic and diastolic blood pressure, Arterial stiffness, and central and aortic blood pressure (which are assessed using Vascular Flow and wave measurement equipment, SphygmoCor Central Pressure system from AtCor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Metabolic Rate (RMR)</measure>
    <time_frame>6 to 12 weeks post Linagliptin</time_frame>
    <description>(RMR, similar to Resting Energy expenditure measurement) at baseline and post therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 1 pill daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linagliptin 5mg once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>5 mg tablet once daily for 12 weeks</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>TRADJENTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 40-70 years

          -  Diagnosis of type 2 diabetes within the previous 15 years using criteria of the
             American Diabetes Association

          -  Currently being treated with 1-2 grams/day of metformin, or insulin or both stably

          -  Hemoglobin A1c (HbA1C) between 6.5% to 10.0% (both inclusive)

          -  Body Mass Index (BMI) between 25 and 39.9 kg/m2 (both inclusive)

          -  Chronic Kidney disease (CKD) Stages 1-3, Creatinine clearance (CrCl) less than 90 and
             more than 29

        Exclusion Criteria:

          -  Type 1 diabetes

          -  History of Diabetic Ketoacidosis (DKA) or hyperosmolar nonketotic coma

          -  Hemoglobinopathies with low hematocrit (Below 28 Units)

          -  History of pancreatitis

          -  History of cancer within the past 5 years (except basal cell carcinoma)

          -  Previous cardiovascular or cerebrovascular event within 6 months of screening or
             active or clinically significant coronary and/or Peripheral Vascular Disease (PVD)

          -  Statin use started in the last 3 month

          -  Current use of oral or injectable anti-diabetic medication other than Metformin and
             insulin

          -  Consistent use of steroids within the last 3 months

          -  Any active wounds, or surgery within the past 3 months

          -  Inflammatory disease, or the chronic use of anti-inflammatory drugs within the past 3
             months

          -  Untreated hyper/hypothyroidism

          -  Contraindications to moderate exercise

          -  Implanted devices that might interact with the tanita scale

          -  Pre-existing liver disease and/or Alanine aminotransferase (ALT) and Aspartate
             Aminotransferase (AST) &gt; 2.5 times Under the Normal Limits (UNL)

          -  Systolic blood pressure &gt; 140 mmHg or diastolic blood pressure&gt; 90 mmHg

          -  Serum creatinine levels â‰¥ 2.0

          -  CKD Stages 4 and 5 (estimated CrCl &lt;30 mL/min)

          -  Triglycerides &gt; 450 mg/dL

          -  Known allergies or hypersensitivities to Linagliptin or Dipeptidyl peptidase-4 (DDP-4)
             inhibitors

          -  Treatment with cytochrome p450 (CYP 3A4) inhibitors

          -  Women of child bearing age who are unwilling or unable to use an acceptable method to
             avoid pregnancy for the entire study

          -  Prisoners or subjects that are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (e.g. infectious disease) illness

          -  Additionally, patients who are active smokers, patients who are pregnant, nursing
             women, and post-menopausal women who are on hormone replacement therapy will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabyasachi Sen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Faculty Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fiona Dore, BS</last_name>
    <phone>202-741-2342</phone>
    <email>fdore@mfa.gwu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Embersit, BS</last_name>
    <phone>202-741-2798</phone>
    <email>dembersit@mfa.gwu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Dore, BS</last_name>
      <phone>202-741-2342</phone>
      <email>fdore@mfa.gwu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Sabyasachi Sen</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Endothelial cells</keyword>
  <keyword>Cellular biomarker</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>CD34+</keyword>
  <keyword>Impaired renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no current plan to share IPD with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

